Abby Med

Abby Med is a private U.S. oncology biotech focused on developing a novel class of triphenylmethane-based small molecules for malignant gliomas, including glioblastoma. Publicly available descriptions indicate the company is advancing non-toxic, low-cost compounds that have shown activity against human glioma cell lines and is also developing encapsulation approaches for non-invasive delivery. The company appears to be associated with co-founder Jack Arbiser and Atlanta, Georgia. Available public sources describe Abby Med as an active for-profit company, but there is little evidence of an advanced clinical pipeline or public-market activity. Based on the available information, Abby Med should be viewed as an early-stage, preclinical cancer therapeutics company rather than a commercial-stage pharma business.